Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia

References

• LiebermanJAIs schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspectiveBiol Psychiatry199946672973910494440
   PubMed Web of Science ®Google Scholar
• KaneJMTreatment strategies to prevent relapse and encourage remissionJ Clin Psychiatry200768Suppl 14273018284275
   PubMed Web of Science ®Google Scholar
• MüllerNMechanisms of relapse prevention in schizophreniaPharmacopsychiatry200437Suppl 2S141S14715546066
   PubMed Web of Science ®Google Scholar
• CrumlishNWhittyPClarkeMBeyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosisBr J Psychiatry20091941182419118320
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet201237998312063207122560607
   PubMed Web of Science ®Google Scholar
• PatelMXTaylorMDavidASAntipsychotic long-acting injections: mind the gapBr J Psychiatry Suppl200952S1S419880911
   PubMedGoogle Scholar
• RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501
   PubMed Web of Science ®Google Scholar
• LindenmayerJPLiu-SeifertHKulkarniPMMedication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJ Clin Psychiatry200970799099619497244
   PubMed Web of Science ®Google Scholar
• KirsonNYWeidenPJYermakovSEfficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designsJ Clin Psychiatry201374656857523842008
   PubMed Web of Science ®Google Scholar
• MorkenGWidenJHGraweRWNon-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry200883218447935
   PubMed Web of Science ®Google Scholar
• PerkinsDOGuHWeidenPJMcEvoyJPHamerRMLiebermanJAPredictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter studyJ Clin Psychiatry200869110611318312044
   PubMed Web of Science ®Google Scholar
• VerdouxHLengronneJLiraudFMedication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjectsActa Psychiatr Scand2000102320321011008856
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• ColdhamELAddingtonJAddingtonDMedication adherence of individuals with a first episode of psychosisActa Psychiatr Scand2002106428629012225495
   PubMed Web of Science ®Google Scholar
• MoisanJGrégoireJPPatterns of discontinuation of atypical antipsychotics in the province of Québec: a retrospective prescription claims database analysisClin Ther201032Suppl 1S21S3120152549
   PubMed Web of Science ®Google Scholar
• CooperDMoisanJGrégoireJPAdherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophreniaJ Clin Psychiatry200768681882517592904
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDEFuriakNMMontgomeryWMedication adherence levels and differential use of mental-health services in the treatment of schizophreniaBMC Res Notes20092619138402
   PubMedGoogle Scholar
• BarnesTREvidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for PsychopharmacologyJ Psychopharmacol201125556762021292923
   PubMed Web of Science ®Google Scholar
• HasanAFalkaiPWobrockTWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistanceWorld J Biol Psychiatry201213531837822834451
   PubMed Web of Science ®Google Scholar
• StaringABVan der GaagMKoopmansGTTreatment adherence therapy in people with psychotic disorders: randomised controlled trialBr J Psychiatry2010197644845521119150
   PubMed Web of Science ®Google Scholar
• NovickDHaroJMSuarezDPerezVDittmannRWHaddadPMPredictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophreniaPsychiatry Res201017620310911320185182
   PubMed Web of Science ®Google Scholar
• RitchieCWHarriganSMastwykMMacfarlaneSCheesmanNAmesDPredictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years durationInt J Geriatr Psychiatry201025441141819946860
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHFariesDEZhuBErnstFRSwartzMSSwansonJWMedication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careJ Clin Psychiatry200667345346016649833
   PubMed Web of Science ®Google Scholar
• ZhornitskySStipEOral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic reviewSchizophr Res Treatment2012201240717122966436
   PubMedGoogle Scholar
• PeuskensJOlivaresJMPecenakJTreatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countriesCurr Med Res Opin201026350150920014981
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MartinezABurónJAAlonso-EscolanoDRodriguez-MoralesACost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in SpainAppl Health Econ Health Policy200861415318774869
   PubMedGoogle Scholar
• OlivaresJMRodriguez-MoralesADielsJPoveyMJacobsAZhaoZLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)Eur Psychiatry200924528729619195847
   PubMed Web of Science ®Google Scholar
• OffordSWongBMirskiDBakerRALinJHealthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oralJ Med Econ201316223123923163287
   PubMedGoogle Scholar
• PengXAscher-SvanumHFariesDConleyRRSchuhKJDecline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophreniaClinicoecon Outcomes Res2011391421935327
   PubMedGoogle Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• RenXSCriveraCSikiricaMDiraniRQianSKazisLEEvaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the Veterans Health AdministrationJ Clin Pharm Ther201136338338921062329
   PubMed Web of Science ®Google Scholar
• BrnabicAJKelinKAscher-SvanumHMontgomeryWKadziolaZKaragianisJMedication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational studyInt J Clin Pract201165994595321849009
   PubMed Web of Science ®Google Scholar
• ShiLAscher-SvanumHZhuBFariesDMontgomeryWMarderSRCharacteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophreniaPsychiatr Serv200758448248817412849
   PubMed Web of Science ®Google Scholar
• ZhuBAscher-SvanumHShiLFariesDMontgomeryWMarderSRTime to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophreniaPsychiatr Serv200859331531718308914
   PubMed Web of Science ®Google Scholar
• RosenheckRAKrystalJHLewRLong-acting risperidone and oral antipsychotics in unstable schizophreniaN Engl J Med2011364984285121366475
   PubMed Web of Science ®Google Scholar
• HaddadPMTaylorMNiazOSFirst-generation antipsychotic long-acting injections v oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studiesBr J Psychiatry Suppl200952S20S2819880913
   PubMedGoogle Scholar
• Fusar-PoliPKemptonMJRosenheckRAEfficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trialsInt Clin Psychopharmacol2013282576623165366
   PubMed Web of Science ®Google Scholar
• KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophr Bull Epub122013
   Web of Science ®Google Scholar
• KaneJMKishimotoTCorrellCUAssessing the comparative effectiveness of long-acting injectable vs oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatryJ Clin Epidemiol201366Suppl 8S37S4123849151
   PubMed Web of Science ®Google Scholar
• BartzokisGLuPHRavenEPImpact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophreniaSchizophr Res20121401–312212822809684
   PubMed Web of Science ®Google Scholar
• BartzokisGSchizophrenia: breakdown in the well-regulated lifelong process of brain development and maturationNeuropsychopharmacology200227467268312377404
   PubMed Web of Science ®Google Scholar
• AndreasenNCLiuDZiebellSVoraAHoBCRelapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI studyAm J Psychiatry2013170660961523558429
   PubMed Web of Science ®Google Scholar
• TaylorMNgKYShould long-acting (depot) antipsychotics be used in early schizophrenia? A systematic reviewAust N Z J Psychiatry201347762463023209308
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhaoFDetkeHCEarly response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophreniaBMC Psychiatry20111115221943257
   PubMed Web of Science ®Google Scholar
• CriveraCDeSouzaCKozmaCMDiraniRDMaoLMacfaddenWResource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)BMC Psychiatry20111116821999370
   PubMed Web of Science ®Google Scholar
• TaylorMCurrieALloydKPriceMPeperellKImpact of risperidone long acting injection on resource utilization in psychiatric secondary careJ Psychopharmacol200822212813118308820
   PubMed Web of Science ®Google Scholar
• LinJWongBOffordSMirskiDHealthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophreniaJ Behav Health Serv Res201340335536623579871
   PubMed Web of Science ®Google Scholar
• BeraROffordSZubekDImpact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychoticsJ Med Econ201316452252823360177
   PubMedGoogle Scholar
• FuriakNMGahnJCKleinRWCamperSBSummersKHEstimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision modelAnn Gen Psychiatry20121112923157721
   PubMed Web of Science ®Google Scholar
• LloydKLatifMASimpsonSShresthaKLSwitching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcomeHum Psychopharmacol201025324325220373476
   PubMed Web of Science ®Google Scholar
• De MarinisTSaleemPTGluePSwitching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophreniaPharmacopsychiatry200740625726318030649
   PubMed Web of Science ®Google Scholar
• MacfaddenWDeSouzaCCriveraCAssessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsBMC Psychiatry20111116721999346
   PubMed Web of Science ®Google Scholar
• WitteMMCaseMGSchuhKJAscher-SvanumHEffects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophreniaCurr Med Res Opin201228331532322236137
   PubMed Web of Science ®Google Scholar
• LambertMDe MarinisTPfeilJNaberDSchreinerAEstablishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatmentEur Psychiatry201025422022919926263
   PubMed Web of Science ®Google Scholar
• LlorcaPMBouhoursPMoreau-MalletVImproved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidoneEncephale200834217017818597725
   PubMed Web of Science ®Google Scholar
• OsborneRHDaltonAHertelJSchroverRSmithDKHealth-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off studyHealth Qual Life Outcomes2012103522472127
   PubMed Web of Science ®Google Scholar
• PatelMXHaddadPMChaudhryIBMcLoughlinSHusainNDavidASPsychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 yearsJ Psychopharmacol201024101473148219477883
   PubMed Web of Science ®Google Scholar
• WestJCMarcusSCWilkJCountisLMRegierDAOlfsonMUse of depot antipsychotic medications for medication nonadherence in schizophreniaSchizophr Bull2008345995100118093962
   PubMed Web of Science ®Google Scholar
• HamannJMendelRHeresSLeuchtSKisslingWHow much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?Eur Neuropsychopharmacol201020427627920133108
   PubMed Web of Science ®Google Scholar
• HeresSHamannJKisslingWLeuchtSAttitudes of psychiatrists toward antipsychotic depot medicationJ Clin Psychiatry200667121948195317194274
   PubMed Web of Science ®Google Scholar
• JaegerMRosslerWAttitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatristsPsychiatry Res20101751–2586220004980
   PubMed Web of Science ®Google Scholar
• HeresSReichhartTHamannJMendelRLeuchtSKisslingWPsychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophreniaEur Psychiatry201126529730120570493
   PubMed Web of Science ®Google Scholar
• WaddellLTaylorMAttitudes of patients and mental health staff to antipsychotic long-acting injections: systematic reviewBr J Psychiatry Suppl200952S43S5019880916
   PubMedGoogle Scholar
• HeresSSchmitzFSLeuchtSPajonkFGThe attitude of patients towards antipsychotic depot treatmentInt Clin Psychopharmacol200722527528217690596
   PubMed Web of Science ®Google Scholar
• WalburnJGrayRGournayKQuraishiSDavidASSystematic review of patient and nurse attitudes to depot antipsychotic medicationBr J Psychiatry200117930030711581109
   PubMed Web of Science ®Google Scholar
• RossiGFredianiSRossiRRossiALong-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observationsBMC Psychiatry20121212222909285
   PubMed Web of Science ®Google Scholar
• KelinKBrnabicAJNewtonRBaseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherencePatient Prefer Adherence2010430131120859457
   PubMed Web of Science ®Google Scholar
• KelinKLambertTJrBrnabicAJTreatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherencePatient Prefer Adherence2011521322221660103
   PubMed Web of Science ®Google Scholar
• PuschnerBAngermeyerMCLeeseMCourse of adherence to medication and quality of life in people with schizophreniaPsychiatry Res2009165322423319155070
   PubMed Web of Science ®Google Scholar
• McCabeRBullenkampJHanssonLThe therapeutic relationship and adherence to antipsychotic medication in schizophreniaPLoS One201274e3608022558336
   PubMed Web of Science ®Google Scholar
• MohamedSRosenheckRMcEvoyJSwartzMStroupSLiebermanJACross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophreniaSchizophr Bull200935233634618586692
   PubMed Web of Science ®Google Scholar
• DibonaventuraMGabrielSDupclayLGuptaSKimEA patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophreniaBMC Psychiatry2012122022433036
   PubMed Web of Science ®Google Scholar
• PatelMXde ZoysaNBernadtMDavidASA cross-sectional study of patients’ perspectives on adherence to antipsychotic medication: depot versus oralJ Clin Psychiatry200869101548155619192437
   PubMed Web of Science ®Google Scholar
• LambertTJPractical management of schizophrenia: the role of long-acting antipsychoticsInt Clin Psychopharmacol EpubJune42013
   Google Scholar
• KaneJMGarcia-RiberaCClinical guideline recommendations for antipsychotic long-acting injectionsBr J Psychiatry Suppl200952S63S6719880920
   PubMedGoogle Scholar
• BuchananRWKreyenbuhlJKellyDLThe 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSchizophr Bull2010361719319955390
   PubMed Web of Science ®Google Scholar
• KreyenbuhlJBuchananRWDickersonFBDixonLBThe Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009Schizophr Bull20103619410319955388
   PubMed Web of Science ®Google Scholar
• Canadian Psychiatric AssociationClinical practice guidelines. Treatment of schizophreniaCan J Psychiatry20055013 Suppl 17S57S16529334
   PubMedGoogle Scholar
• FalkaiPWobrockTLiebermanJGlenthojBGattazWFMöllerHJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophreniaWorld J Biol Psychiatry20067154016509050
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry2004161Suppl 215615000267
   PubMed Web of Science ®Google Scholar
• VelliganDIMedellinEDraperMBarriers to, and strategies for, starting a long acting injection clinic in a community mental health centerCommunity Ment Health J201147665465921253830
   PubMed Web of Science ®Google Scholar
• NasrallahHAThe case for long-acting antipsychotic agents in the post-CATIE eraActa Psychiatr Scand2007115426026717355516
   PubMed Web of Science ®Google Scholar